江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）第九 届董事会第三次会议于 2025 年 4 月 1 日以通讯方式发出会议通知，于 2025 年 4 月 11 日上午在公司会议室以现场结合通讯方式召开。会议应出席董事 9 名，实 际出席会议董事 9 名。公司监事及高管列席了会议。会议由公司董事长沈学如先 生主持，符合《公司法》及公司《章程》的有关规定。会议经认真审议，通过如 下议案： 江苏澳洋健康产业股份有限公司 一、审议通过《2024 年度总经理工作报告》 证券代码：002172 证券简称：澳洋健康 公告编号：2025-06 第九届董事会第三次会议决议公告 关联董事李静女士回避表决。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，并对公告的 虚假记载、误导性陈述或者重大遗漏负连带责任。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 三、审议通过《2024 年度财务决算报告》 报告期内，公司实现营业总收入 200,977.52 万元，比上年同期减少 7.54%； 实现营业利润 6,760.86 ...

第九届董事会独立董事专门会议第二次会议决议 江苏澳洋健康产业股份有限公司 第九届董事会独立董事专门会议第二次会议决议 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号－主板上市公司规范运作》等相关法 律法规、规范性文件及《公司章程》《独立董事专门会议工作制度》的有关规定， 江苏澳洋健康产业股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开 了公司第九届董事会独立董事专门会议第二次会议，会议应到独立董事 3 名，实 到独立董事 3 名。本次会议的召集、召开和表决程序符合有关法律法规、规范性 文件及《公司章程》的规定。独立董事在认真审阅相关材料的基础上，基于独立 客观的原则，本着对公司及全体股东负责的态度，经各位独立董事审议和表决， 形成以下决议： 一、审议通过了《关于 2024 年度利润分配的预案》 经审议，我们认为，2024 年度利润分配预案充分考虑了公司现阶段的经营状 况、资金需求及未来发展等因素，有利于公司的持续稳定和健康发展，不存在损 害投资者利益的情况，该预案符合公司实际情况。因此，独立董事一致同意该议 案，并提交公司董 ...

2024 年度利润分配预案的公告 江苏澳洋健康产业股份有限公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示 1、截至2024年12月31日，合并报表归属于上市公司股东的未分配利润总额 -1,932,522,582.60元，母公司报表未分配利润总额为-2,053,809,749.41元。公司2024 年度利润分配预案为：不派发现金红利，不送红股，不以公积金转增股本。 2.公司利润分配预案不涉及《深圳证券交易所股票上市规则》第9.8.1条相关规定 的可能被实施其他风险警示情形。 一、审议程序 江苏澳洋健康产业股份有限公司（以下简称"公司"）于2025年4月11日召开的 第九届董事会第三次会议和第九届监事会第三次会议，以同意9票，反对0 票，弃权0票的表决结果审议通过了《2024年度利润分配的预案》。 证券代码：002172 证券简称：澳洋健康 公告编号：2025-09 二、2024年度利润分配预案的基本内容 经立信会计师事务所（特殊普通合伙）出具的信会师报字[2025]第ZA10840号 《审计报告》确认，2024年 ...

澳洋健康（002172）公告，2024年营业收入20.1亿元，同比下降7.54%。归属于上市公司股东的净利润 4056.19万元，同比下降18.36%。基本每股收益0.05元/股，同比下降16.67%。公司计划不派发现金红 利，不送红股，不以公积金转增股本。 ...

Core Viewpoint - Aoyang Health (002172) has decided to terminate the capital increase plan for its wholly-owned subsidiary due to changes in the market environment, following discussions with the investment parties [1] Group 1 - The company originally planned to raise capital of 30.6 million yuan and 48.5 million yuan from Juxin Investment and Juliy Investment, respectively [1] - The decision to terminate the capital increase has been approved by the company's board of directors and the supervisory board, and it will be submitted for shareholder meeting approval [1] - The capital increase plan has not been substantively implemented, as no agreements were signed and no payments were made, meaning it will not have a significant impact on the company's operations [1]

Financial Performance - The company's operating revenue for 2024 was approximately ¥2.01 billion, a decrease of 7.54% compared to ¥2.17 billion in 2023[17]. - The net profit attributable to shareholders for 2024 was approximately ¥40.56 million, down 18.36% from ¥49.68 million in 2023[17]. - The net profit after deducting non-recurring gains and losses increased by 19.35% to approximately ¥32.58 million in 2024, compared to ¥27.29 million in 2023[17]. - The basic earnings per share for 2024 was ¥0.05, a decrease of 16.67% from ¥0.06 in 2023[17]. - Total assets at the end of 2024 were approximately ¥2.05 billion, down 8.49% from ¥2.24 billion at the end of 2023[17]. - The weighted average return on equity for 2024 was 35.53%, a decrease of 36.43% from 71.96% in 2023[17]. - The gross margin for medical services was 19.92%, while for pharmaceutical logistics it was 6.73%, indicating a slight decrease in both segments[49]. - The company reported a net loss from investment of ¥1,312,375.05, which constituted -2.01% of total profit[60]. - The company reported a net profit of -15.39 million yuan for 2022, a significant deviation from the initial profit forecast of 5 to 7.5 million yuan[97]. - The company reported a net profit of 900,000, which remains unchanged from the previous year, indicating stability in profitability despite market fluctuations[200]. Cash Flow and Liquidity - The net cash flow from operating activities for 2024 was approximately ¥438.65 thousand, a significant decline of 99.19% from ¥54.30 million in 2023[17]. - The company reported a significant decline in cash flow from operating activities, indicating potential liquidity issues[17]. - Cash flow from operating activities for 2024 was 438,651.63, down from 54,303,048.16 in 2023, showing a decline of approximately 99.2%[193]. - The total cash inflow from financing activities in 2024 was 1,335,831,659.50, compared to 2,001,230,800.48 in 2023, a decrease of about 33.3%[194]. - The net cash flow from financing activities for 2024 was -49,545,729.00, compared to -11,428,440.96 in 2023, indicating a worsening of approximately 334.5%[194]. - The total cash and cash equivalents at the end of 2024 were 266,066,794.14, down from 353,971,272.78 in 2023, a decrease of about 24.6%[194]. - The company's total liabilities decreased, with cash outflow for debt repayment in 2024 at 1,204,074,220.57, down from 1,553,676,455.34 in 2023, a reduction of about 22.5%[196]. Investments and Growth Strategies - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new health technologies and products[95]. - The company plans to expand its market presence and invest in new product development, aiming for a revenue growth target of 10% for the upcoming fiscal year[198]. - The company has initiated a strategic review of potential acquisitions to enhance its competitive position in the market[198]. - The company plans to enhance its medical service network and increase market share in Zhangjiagang, aiming for a more integrated healthcare model[73]. - The company is actively seeking new growth opportunities in the health industry, particularly in functional foods and health supplements[44]. Regulatory and Governance - The company has established a comprehensive governance structure, adhering to regulations and ensuring independent operations from its controlling shareholder[83]. - The company is focusing on improving internal control systems and enhancing corporate governance in response to regulatory feedback[97]. - The company plans to strengthen its information disclosure management to comply with regulatory requirements[97]. - The company has implemented a robust information disclosure and investor relations management system to maintain transparency and communication with stakeholders[81]. - The company has faced scrutiny for its financial reporting practices, highlighting the need for improved accuracy in future disclosures[97]. Market Position and Industry Outlook - The healthcare management industry in China is projected to exceed 1.3 trillion RMB by the end of 2025, with a stable year-on-year growth rate[32]. - The government plans to increase healthcare spending to a new high in 2025, focusing on enhancing grassroots medical service capabilities[29]. - The digitalization of healthcare services is expected to improve resource utilization and patient experience significantly[30]. - The application of artificial intelligence in healthcare is anticipated to enhance diagnostic accuracy and treatment efficiency, particularly in oncology and cardiovascular diseases[31]. Shareholder and Management Information - The annual shareholders meeting had a participation rate of 31.51% on May 17, 2024[84]. - The first extraordinary shareholders meeting had a participation rate of 33.33% on June 24, 2024[84]. - The second extraordinary shareholders meeting had a participation rate of 32.16% on November 25, 2024[84]. - The total shares held by directors and senior management at the end of the reporting period was 613,840 shares[86]. - Director Yuan Yibing resigned as CFO on May 17, 2024, due to personal reasons[86]. - The company has a diverse board with members holding various positions in multiple subsidiaries[87][88][89]. Operational Efficiency - The company has established partnerships with three major healthcare providers to enhance service delivery and expand its market reach[92]. - Jiangsu Aoyang's operational efficiency has improved, with a reduction in operational costs by 5% year-over-year[93]. - The company has identified cost-saving strategies that could reduce operational expenses by 12% in the next fiscal year[144]. Social Responsibility and Community Engagement - The company has actively participated in social responsibility initiatives, including free medical consultations in communities[120].

Group 1 - The core viewpoint of the articles highlights the performance and market position of Aoyang Health, which has a current stock price of 3.27 yuan, reflecting a 2.51% increase, with a rolling PE ratio of 51.38 times and a total market capitalization of 2.504 billion yuan [1][2] - Aoyang Health's main business focuses on health care, including pharmaceutical logistics, medical services, and health care services, with four hospitals established in Zhangjiagang City [1] - The company has received various accolades, including being recognized as a tertiary comprehensive hospital and passing JCI re-evaluation, which enhances its reputation in the health sector [1] Group 2 - For the third quarter of 2024, Aoyang Health reported an operating income of 1.501 billion yuan, a year-on-year decrease of 7.54%, and a net profit of 38.6781 million yuan, down 2.39% year-on-year, with a sales gross margin of 13.72% [2] - In terms of industry comparison, Aoyang Health's PE ratio of 51.38 is higher than the industry average of 46.79 and the industry median of 47.81 [2] - As of September 30, 2024, Aoyang Health had 56,603 shareholders, an increase of 601 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

4月7日，澳洋健康今日收盘3.12元，下跌10.09%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到49.02倍，总市值23.89亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均45.72倍，行业中值41.83倍，澳洋健康排 名第31位。 资金流向方面，4月7日，澳洋健康主力资金净流出1008.19万元，近5日总体呈流出状态，5日共流出 1311.64万元。 江苏澳洋健康产业股份有限公司主营业务为健康医疗。公司主要产品及服务为医药物流、医疗服务、康 养服务。公司在张家港市已拥有澳洋医院、杨舍分院、三兴分院、顺康医院四家医院。其中,澳洋医院 被评为三级综合医院并通过JCI认证医院复评，助力于提升上市公司在大健康领域的知名度，树立了良 好的企业形象，对公司的经营发展起到了积极影响；荣获第七届全国医院品管圈大赛三等奖、改善医疗 服务示范医院、苏州市级临床重点专科、中国上市医服务企csr30强，入围了"2019年医院品管圈比赛优 秀圈组一等奖"。 序号股票简称PE(TTM)PE(静)市净率总市值(元)31澳洋健康49.0248.0918.0223.89亿行业平均 45.7240.943. ...

Core Viewpoint - Aoyang Health's stock closed down 3.10% with a rolling P/E ratio of 54.05 times and a total market capitalization of 2.634 billion yuan, indicating a decline in performance compared to industry averages [1][2]. Company Summary - Aoyang Health's main business focuses on health care, including pharmaceutical logistics, medical services, and health care services. The company operates four hospitals in Zhangjiagang City, with Aoyang Hospital recognized as a tertiary comprehensive hospital and JCI certified, enhancing its reputation in the health sector [1]. - The company achieved a revenue of 1.501 billion yuan in the latest quarterly report, reflecting a year-on-year decrease of 7.54%. The net profit was 38.6781 million yuan, down 2.39%, with a sales gross margin of 13.72% [2]. Industry Summary - The average P/E ratio for the medical services industry is 44.02 times, with a median of 43.09 times, positioning Aoyang Health at the 32nd rank within the industry [1][2]. - The company experienced a net outflow of 2.1705 million yuan in principal funds on March 24, with a total outflow of 73.5313 million yuan over the past five days, indicating a negative trend in investor sentiment [1].

2025 年第一次临时股东大会会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-05 江苏澳洋健康产业股份有限公司 2025 年第一次临时股东大会会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 2、本次股东大会未涉及变更前次股东大会决议的情况； 3、本次股东大会采取现场投票、网络投票相结合的方式召开。 二、 会议召开的情况 1、 召开时间：2025 年 2 月 6 日下午 14:00； 一、 特别提示 2、 召开地点：张家港市杨舍镇塘市澳洋国际大厦 A 座会议室； 1、本次股东大会召开期间没有发生增加、否决或变更议案的情况； 3、 召开方式：本次股东大会议采取现场投票与网络投票相结合的方式； 4、 召集人：江苏澳洋健康产业股份有限公司董事会； 5、 主持人：董事长沈学如； 6、 会议的召开符合《公司法》《股票上市规则》及《公司章程》的相关规 定。 三、 会议的出席情况 1、出席会议股东的总体情况： 通过现场和网络投票的股东 389 人，代表股份 8,008,050 股，占上市公司总 股份的 1.0458%。 2、现场会议 ...